The Institute for Transfusion Medicine

Part III, Line 3

“Effective january 1, 2020, the institute for transfusion medicine ("itxm") merged into vitalant. As a result of the merger, itxm transferred all its assets to vitalant. Itxm continues to operate services and programs as previously, now as an integral part of the operations of vitalant. Part vi, section a, lines 6, 7a and 7b effective march 1, 2017 the institute for transfusion medicine ("itxm")amended its articles of incorporation and bylaws such that blood systems inc ("bsi") became itxm's sole corporate member. During the prior tax year bsi formally changed it's name to vitalant. As itxm's sole corporate member, vitalant has the power to elect and appoint itxm's board of directors and certain reserved powers with respect to itxm including the power to amended itxm's articles of incorporation and bylaws; itxm merger, consolidation or dissolution; authority over decisions related to organizational structure, strategic goals, economic objectives, major operating policies, and significant financial accounting principles and practices; selection, evaluation, replacement and compensation of itxm senior executive officers and board members; selection of external cpas to examine and audit itxm's annual financial statements; selection of external itxm legal counsel to advise the itxm board; and approval of major itxm plans, commitments and initiatives. Part vi, section b, line 11 the 990 is completed by management and is reviewed by an external, independent accounting firm. The 990 has been reviewed by executive leadership and a copy has been sent to vitalant's board, as the surviving entity from the merger, for their review prior to filing. Part vi, section b, line 12c each year, the board of directors and senior management are required to sign and return a conflict of interest form to company counsel. Any conflicts disclosed are discussed in executive session with the board and resolved. In addition, in preparation for the form 990 filing, the directors, officers and key employees identified are required to respond to a comprehensive conflict of interest and family relationship questionaire. Any conflicts are discussed with the board and disclosed appropriately on the form 990. Part vi, section b, line 15 the board of trustees of vitalant has a compensation and human resources committee whose purpose, among other things, is to hire an independent consulting firm once every 2-3 years to provide data on competitiveness of salaries and benefits for the ceo, officers and other key employees of the corporation. This process is being conducted in 2020. The members of the human resources and compensation committee of the board are all independent trustees and include no members of management. The recommendatons of the committee are reviewed by the entire board prior to approval. Compensation for these individuals is set and approved by the board each year. The results of these discussions, reviews and approvals are documented in the executive session minutes of the board meetings. Part vi, section c, line 19 the organization makes its governing documents, conflict of interest policy and financial statements available to the public upon request. Part xi, line 9 transfer of virginia blood services intra-company and retained earnings to itxm $7,172,493 and the transfer of itxm net assets, due to merger, to vitalant $9,617,680.”